Structure Therapeutics (GPCR) Gains from Sales and Divestitures (2023 - 2025)
Structure Therapeutics (GPCR) recorded quarterly Gains from Sales and Divestitures of $308000.0 in Q4 2025, up 4300.0% quarter-over-quarter from $7000.0 in Q4 2024, and up 4300.0% on a YoY basis from $7000.0 in Q4 2024.
Structure Therapeutics (GPCR) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends
Structure Therapeutics' Gains from Sales and Divestitures history runs 3 years deep, the most recent figure standing at $308000.0 for Q4 2025.
- In Q4 2025, Gains from Sales and Divestitures rose 4300.0% year-over-year to $308000.0; the TTM figure through Dec 2025 stood at $308000.0 (up 4300.0% YoY), while the FY2025 annual figure was $308000.0, up 4300.0% from the prior year.
- Gains from Sales and Divestitures was $308000.0 for Q4 2025 at Structure Therapeutics, up from $7000.0 in the prior quarter.
- In the past five years, Gains from Sales and Divestitures ranged from a high of $327000.0 in Q2 2023 to a low of $7000.0 in Q4 2024.
- Historically, Gains from Sales and Divestitures has averaged $256833.3 across 3 years, with a median of $317500.0 in 2023.
- The sharpest annual moves came in 2024 and 2025: Gains from Sales and Divestitures tumbled 97.86% in 2024, then soared 4300.0% in 2025.
- A 3-year view of Gains from Sales and Divestitures shows it stood at $327000.0 in 2023, then sank by 97.86% to $7000.0 in 2024, then jumped by 4300.0% to $308000.0 in 2025.
- The last three Gains from Sales and Divestitures figures came in at $308000.0 (Q4 2025), $7000.0 (Q4 2024), and $327000.0 (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Structure Therapeutics | 9.35 Bn | 9.35 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 308,000.00 |
| Dec 31, 2025 | 308,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2023 | 327,000.00 |
| Dec 31, 2023 | 327,000.00 |
| Sep 30, 2023 | 327,000.00 |
| Sep 30, 2023 | 327,000.00 |
| Jun 30, 2023 | 327,000.00 |
| Jun 30, 2023 | 327,000.00 |
| Mar 31, 2023 | 245,000.00 |
| Mar 31, 2023 | 245,000.00 |